Indeed, breast cancers with any degree of HER2 amplification appear to demonstrate sensitivity to HER2 targeted therapy; [24] however, much higher levels of HER2 or FGFR2 expression are required before effective therapeutic targeting is seen in gastric cancer [25,26]. This evidence concerns the gene ERBB2 and breast cancer.